These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38506430)

  • 1. Sex differences in mortality and liver-related events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zhou H; Chen H; Lu H; Wu B; Zhang S; Gu Y; Zhou G; Xiang J; Yang J
    Liver Int; 2024 Jul; 44(7):1600-1609. PubMed ID: 38506430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis.
    Huang S; Bao Y; Zhang N; Niu R; Tian L
    Endocrine; 2024 Jul; 85(1):134-141. PubMed ID: 37253855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants.
    Wang Y; O'Neil A; Jiao Y; Wang L; Huang J; Lan Y; Zhu Y; Yu C
    BMC Med; 2019 Jul; 17(1):136. PubMed ID: 31296205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Souza M; Diaz I; Barchetta I; Mantovani A
    Liver Int; 2024 Jan; 44(1):6-14. PubMed ID: 37833849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals.
    Souza M; Diaz I; Al-Sharif L
    Hepatol Int; 2024 Oct; 18(5):1396-1415. PubMed ID: 39117942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Alon L; Corica B; Raparelli V; Cangemi R; Basili S; Proietti M; Romiti GF
    Eur J Prev Cardiol; 2022 May; 29(6):938-946. PubMed ID: 34939092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Ann Hepatol; 2024; 29(3):101288. PubMed ID: 38278181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men.
    Hwang YC; Ahn HY; Park SW; Park CY
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1131-1137.e5. PubMed ID: 29158157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis.
    Zhang X; Mou Y; Aribas E; Amiri M; Nano J; Bramer WM; Kavousi M; de Knegt RJ; Asllanaj E; Ghanbari M
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
    Bisaccia G; Ricci F; Khanji MY; Sorella A; Melchiorre E; Iannetti G; Galanti K; Mantini C; Pizzi AD; Tana C; Renda G; Fedorowski A; De Caterina R; Gallina S
    Curr Probl Cardiol; 2023 Jun; 48(6):101643. PubMed ID: 36773944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: A systematic review and meta-analysis.
    Saokaew S; Kanchanasurakit S; Thawichai K; Duangprom P; Wannasri M; Khankham S; Kositamongkol C; Chaiyakunapruk N; Phisalprapa P
    Medicine (Baltimore); 2021 Feb; 100(5):e24557. PubMed ID: 33592910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
    Ha J; Yim SY; Karagozian R
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2496-2507.e5. PubMed ID: 36442727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk of colorectal polyps in men with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Chen W; Wang M; Jing X; Wu C; Zeng Y; Peng J; Cai X
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2051-2065. PubMed ID: 32579269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Gong S; Song J; Wang L; Zhang S; Wang Y
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):132-8. PubMed ID: 26545082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
    Mantovani A; Csermely A; Petracca G; Beatrice G; Corey KE; Simon TG; Byrne CD; Targher G
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):903-913. PubMed ID: 34555346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Thomas JA; Kendall BJ; Dalais C; Macdonald GA; Thrift AP
    Eur J Cancer; 2022 Sep; 173():250-262. PubMed ID: 35944373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.